Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 5, 2016, Pages 909-914

  Wilcock, Donna M ^a   Schmitt, Frederick A ^a   Head, Elizabeth ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Beta amyloid; Cerebral amyloid angiopathy; Hypertension; Hypotension; Microhemorrhages; Moyamoya; Sleep apnea; Stroke

Indexed keywords

ARGINASE 1; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

AGING; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; ATRIOVENTRICULAR SEPTAL DEFECT; CEREBROVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DOWN SYNDROME; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPERTENSION; HYPOTENSION; MOYAMOYA DISEASE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SLEEP DISORDERED BREATHING; VASCULAR COGNITIVE IMPAIRMENT DEMENTIA;

EID: 84949509695     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.11.007     Document Type: Article

References (112)

1. Ait Yahya-Graison E., Aubert J., Dauphinot L., Rivals I., Prieur M., Golfier G., Rossier J., Personnaz L., Creau N., Blehaut H., Robin S., Delabar J.M., Potier M.C. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am. J. Hum. Genet. 2007, 81:475-491.
2. Akinyemi R.O., Mukaetova-Ladinska E.B., Attems J., Ihara M., Kalaria R.N. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Curr. Alzheimer Res. 2013, 10:642-653.
3. Akoudad S., de Groot M., Koudstaal P.J., van der Lugt A., Niessen W.J., Hofman A., Ikram M.A., Vernooij M.W. Cerebral microbleeds are related to loss of white matter structural integrity. Neurology 2013, 81:1930-1937.
4. Alexander M., Petri H., Ding Y., Wandel C., Khwaja O., Foskett N. Morbidity and medication in a large population of individuals with Down syndrome compared to the general Ppopulation. Dev. Med. Child Neurol. 2015.
5. Attems J., Jellinger K.A. The overlap between vascular disease and Alzheimer's disease-lessons from pathology. BMC Med. 2014, 12:206.
6. Back S.A., Kroenke C.D., Sherman L.S., Lawrence G., Gong X., Taber E.N., Sonnen J.A., Larson E.B., Montine T.J. White matter lesions defined by diffusion tensor imaging in older adults. Ann. Neurol. 2011, 70:465-476.
7. Belza M.G., Urich H. Cerebral amyloid angiopathy in Down's syndrome. Clin. Neuropathol. 1986, 5:257-260.
8. Berg J.M., Armstrong D. On the association of moyamoya disease with Down's syndrome. J. Ment. Defic. Res. 1991, 35(Pt 4):398-403.
9. Bittles A.H., Bower C., Hussain R., Glasson E.J. The four ages of Down syndrome. Eur. J. Pub. Health 2007, 17:221-225.
10. Blackwell T., Yaffe K., Ancoli-Israel S., Redline S., Ensrud K.E., Stefanick M.L., Laffan A., Stone K.L. Osteoporotic fractures in men study G. J. Am. Geriatr. Soc. 2011, 59:2217-2225.
11. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995, 274:1049-1057.
12. Bowler J.V., Munoz D.G., Merskey H., Hachinski V. Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1998, 64:18-24.
13. Brattstrom L., Englund E., Brun A. Does Down syndrome support homocysteine theory of arteriosclerosis. Lancet 1987, 14:391-392.
14. Buterbaugh J., Wynstra C., Provencio N., Combs D., Gilbert M., Parthasarathy S. Cerebrovascular reactivity in young subjects with sleep apnea. Sleep 2015, 38:241-250.
15. Cenini G., Dowling A.L., Beckett T.L., Barone E., Mancuso C., Murphy M.P., Levine H., Lott I.T., Schmitt F.A., Butterfield D.A., Head E. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim. Biophys. Acta 2012, 1822:130-138.
16. Chao L.L., Decarli C., Kriger S., Truran D., Zhang Y., Laxamana J., Villeneuve S., Jagust W.J., Sanossian N., Mack W.J., Chui H.C., Weiner M.W. Associations between white matter hyperintensities and beta amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI. PLoS One 2013, 8.
17. Cho E.R., Kim H., Seo H.S., Suh S., Lee S.K., Shin C. Obstructive sleep apnea as a risk factor for silent cerebral infarction. J. Sleep Res. 2013, 22:452-458.
18. Chumlea W.C., Cronk C.E. Overweight among children with trisomy. J. Ment. Defic. Res. 1981, 25(Pt 4):275-280.
19. Collacott R.A., Cooper S.A., Ismail I.A. Multi-infarct dementia in Down's syndrome. J. Intellect. Disabil. Res. 1994, 38(Pt 2):203-208.
20. Cramer S.C., Robertson R.L., Dooling E.C., Scott R.M. Moyamoya and Down syndrome. Stroke 1996, 27:2131-2135.
21. de Borchgrave V., Saussu F., Depre A., de Barsy T. Moyamoya disease and Down syndrome: case report and review of the literature. Acta Neurol. Belg. 2002, 102:63-66.
22. Donahue J.E., Khurana J.S., Adelman L.S. Intracerebral hemorrhage in two patients with Down's syndrome and cerebral amyloid angiopathy. Acta Neuropathol. 1998, 95:213-216.
23. Draheim C.C., McCubbin J.A., Williams D.P. Differences in cardiovascular disease risk between nondiabetic adults with mental retardation with and without Down syndrome. Am. J. Ment. Retard. 2002, 107:201-211.
24. Draheim C.C., Geijer J.R., Dengel D.R. Comparison of intima-media thickness of the carotid artery and cardiovascular disease risk factors in adults with versus without the Down syndrome. Am. J. Cardiol. 2010, 106:1512-1516.
25. Durgan D.J., Bryan R.M. Cerebrovascular consequences of obstructive sleep apnea. J. Am. Heart Assoc. 2012, 1.
26. Englund A., Jonsson B., Zander C.S., Gustafsson J., Anneren G. Changes in mortality and causes of death in the Swedish Down syndrome population. Am. J. Med. Genet. A 2013, 161A:642-649.
27. Esbensen A.J. Health conditions associated with aging and end of life of adults with Down syndrome. Int. Rev. Res. Ment. Retard. 2010, 39:107-126.
28. Esiri M., Chance S., Joachim C., Warden D., Smallwood A., Sloan C., Christie S., Wilcock G., Smith A.D. Cerebral amyloid angiopathy, subcortical white matter disease and dementia: literature review and study in OPTIMA. Brain Pathol. 2015, 25:51-62.
29. Farkas E., Donka G., de Vos R.A., Mihaly A., Bari F., Luiten P.G. Experimental cerebral hypoperfusion induces white matter injury and microglial activation in the rat brain. Acta Neuropathol. 2004, 108:57-64.
30. Freeman S.B., Taft L.F., Dooley K.J., Allran K., Sherman S.L., Hassold T.J., Khoury M.J., Saker D.M. Population-based study of congenital heart defects in Down syndrome. Am. J. Med. Genet. 1998, 80:213-217.
31. Frost J.L., Le K.X., Cynis H., Ekpo E., Kleinschmidt M., Palmour R.M., Ervin F.R., Snigdha S., Cotman C.W., Saido T.C., Vassar R.J., St George-Hyslop P., Ikezu T., Schilling S., Demuth H.U., Lemere C.A. Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am. J. Pathol. 2013, 183:369-381.
32. Fukushima Y., Kondo Y., Kuroki Y., Miyake S., Iwamoto H., Sekido K., Yamaguchi K. Are Down syndrome patients predisposed to moyamoya disease?. Eur. J. Pediatr. 1986, 144:516-517.
33. Glasson E.J., Sullivan S.G., Hussain R., Petterson B.A., Montgomery P.D., Bittles A.H. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin. Genet. 2002, 62:390-393.
34. Goi G., Baquero-Herrera C., Licastro F., Dogliotti G., Corsi M.M. Advanced oxidation protein products (AOPP) and high-sensitive C-reactive protein (hs-CRP) in an "atheroma-free model": Down's syndrome. Int. J. Cardiol. 2006, 113:427-429.
35. Griffin W.S., Barger S.W. Neuroinflammatory cytokines-the common thread in Alzheimer's pathogenesis. US Neurol. 2010, 6:19-27.
36. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Araoz C. Brain interleukin I and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:7611-7615.
37. Griffin W.S.T., Sheng J.G., McKenzie J.E., Royston M.C., Gentleman S.M., Brumback R.A., Cork L.C., Del Bigio M.R., Roberts G.W., Mrak R.E. Life-long overexpression of S100b in Down's syndrome: implications for Alzheimer pathogenesis. Neurobiol. Aging 1998, 19:401-405.
38. Head E., Powell D., Gold B.T., Schmitt F.A. Alzheimer's disease in Down syndrome. European J. Neurodegen. Dis. 2012, 1:353-364.
39. Head E., Silverman W., Patterson D., Lott I.T. Aging and Down syndrome. Curr. Gerontol. Geriatr. Res. 2012, 2012a:412536.
40. Ikeda S., Tokuda T., Yanagisawa N., Kametani F., Ohshima T., Allsop D. Variability of beta-amyloid protein deposited lesions in Down's syndrome brains. Tohoku J. Exp. Med. 1994, 174:189-198.
41. James B.D., Bennett D.A., Boyle P.A., Leurgans S., Schneider J.A. Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA 2012, 307:1798-1800.
42. Jastrzebski K., Kacperska M.J., Majos A., Grodzka M., Glabinski A. Hemorrhagic stroke, cerebral amyloid angiopathy, Down syndrome and the Boston criteria. Neurol. Neurochir. Pol. 2015, 49:193-196.
43. Jellinger K.A. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front. Aging Neurosci. 2013, 5:17.
44. Jiwa N.S., Garrard P., Hainsworth A.H. Experimental models of vascular dementia and vascular cognitive impairment: a systematic review. J. Neurochem. 2010, 115:814-828.
45. Kainth D.S., Chaudhry S.A., Kainth H.S., Suri F.K., Qureshi A.I. Prevalence and characteristics of concurrent Down syndrome in patients with moyamoya disease. Neurosurgery 2013, 72:210-215. discussion 215.
46. Kammoun S., Gold G., Bouras C., Giannakopoulos P., McGee W., Herrmann F., Michel J.P. Immediate causes of death of demented and non-demented elderly. Acta Neurol. Scand. Suppl. 2000, 176:96-99.
47. Kim H., Yun C.H., Thomas R.J., Lee S.H., Seo H.S., Cho E.R., Lee S.K., Yoon D.W., Suh S., Shin C. Obstructive sleep apnea as a risk factor for cerebral white matter change in a middle-aged and older general population. Sleep 2013, 36:709-715B.
48. Krinsky-McHale S.J., Silverman W. Dementia and mild cognitive impairment in adults with intellectual disability: issues of diagnosis. Dev. Disabil. Res. Rev. 2013, 18:31-42.
49. Lai F., Williams M.D. A prospective study of Alzheimer disease in Down Syndrome. Arch. Neurol.-Chicago 1989, 46:849-853.
50. Langa K.M., Foster N.L., Larson E.B. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004, 292:2901-2908.
51. Lemere C.A., Blusztajn J.K., Yamaguchi H., Wisniewski T., Saido T.C., Selkoe D.J. Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down Syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 1996, 3:16-32.
52. Leno C., Mateo I., Cid C., Berciano J., Sedano C. Autoimmunity in Down's syndrome: another possible mechanism of moyamoya disease. Stroke 1998, 29:868-869.
53. Leverenz J.B., Raskind M.A. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp. Neurol. 1998, 150:296-304.
54. Levine D.A., Langa K.M. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics 2011, 8:361-373.
55. Licastro F., Marocchi A., Penco S., Porcellini E., Lio D., Dogliotti G., C M.M. Does Down's syndrome support the homocysteine theory of atherogenesis? Experience in elderly subjects with trisomy 21. Arch. Gerontol. Geriatr. 2006, 43:381-387.
56. Magge S.N., O'Neill K.L., Shults J., Stallings V.A., Stettler N. Leptin levels among prepubertal children with Down syndrome compared with their siblings. J. Pediatr. 2008, 152:321-326.
57. Mann D.M.A., Esiri M.M. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J. Neurol. Sci. 1989, 89:169-179.
58. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
59. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
60. McCarron M.O., Nicoll J.A., Graham D.I. A quartet of Down's syndrome, Alzheimer's disease, cerebral amyloid angiopathy, and cerebral haemorrhage: interacting genetic risk factors. J. Neurol. Neurosurg. Psychiatry 1998, 65:405-406.
61. Melville C.A., Cooper S.A., McGrother C.W., Thorp C.F., Collacott R. Obesity in adults with Down syndrome: a case-control study. J. Intellect. Disabil. Res. 2005, 49:125-133.
62. Mendel T., Bertrand E., Szpak G.M., Stepien T., Wierzba-Bobrowicz T. Cerebral amyloid angiopathy as a cause of an extensive brain hemorrhage in adult patient with Down's syndrome - a case report. Folia Neuropathol. 2010, 48:206-211.
63. Morrison R.A., McGrath A., Davidson G., Brown J.J., Murray G.D., Lever A.F. Low blood pressure in Down's syndrome, a link with Alzheimer's disease?. Hypertension 1996, 28:569-575.
64. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
65. Mrak R.E., Griffin W.S. Trisomy 21 and the brain. J. Neuropathol. Exp. Neurol. 2004, 63:679-685.
66. Murdoch J.C., Rodger J.C., Rao S.S., Fletcher C.D., Dunningham M.G. Down's syndrome: an atheroma-free model?. Br. Med. J. 1977, 2:226-228.
67. Myrelid A., Gustafsson J., Ollars B., Anneren G. Growth charts for Down's syndrome from birth to 18 years of age. Arch. Dis. Child. 2002, 87:97-103.
68. Nagasaka T., Shiozawa Z., Kobayashi M., Shindo K., Tsunoda S., Amino A. Autopsy findings in Down's syndrome with cerebrovascular disorder. Clin. Neuropathol. 1996, 15:145-149.
69. Naito K.S., Sekijima Y., Ikeda S. Cerebral amyloid angiopathy-related hemorrhage in a middle-aged patient with Down's syndrome. Amyloid 2008, 15:275-277.
70. Nishida Y., Akaoka I., Nishizawa T., Maruki M., Maruki K. Hyperlipidaemia in patients with Down's syndrome. Atherosclerosis 1977, 26:369-372.
71. Park M., Raila F.A., Russell W.F. Moyamoya disease in an adult with Down syndrome: comparison of magnetic resonance angiography and conventional angiography. South. Med. J. 1996, 89:89-92.
72. Patel B.N., Pang D., Stern Y., Silverman W., Kline J.K., Mayeux R., Schupf N. Obesity enhances verbal memory in postmenopausal women with Down syndrome. Neurobiol. Aging 2004, 25:159-166.
73. Pearson E., Lenn N.J., Cail W.S. Moyamoya and other causes of stroke in patients with Down syndrome. Pediatr. Neurol. 1985, 1:174-179.
74. Pogribna M., Melnyk S., Pogribny I., Chango A., Yi P., James S.J. Homocysteine metabolism in children with Down syndrome: in vitro modulation. Am. J. Hum. Genet. 2001, 69:88-95.
75. Prasher V.P., Farrer M.J., Kessling A.M., Fisher E.M., West R.J., Barber P.C., Butler A.C. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann. Neurol. 1998, 43:380-383.
76. Provenzano F.A., Muraskin J., Tosto G., Narkhede A., Wasserman B.T., Griffith E.Y., Guzman V.A., Meier I.B., Zimmerman M.E., Brickman A.M., Alzheimer's Disease Neuroimaging I. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?. JAMA Neurol. 2013, 70:455-461.
77. Ramia M., Musharrafieh U., Khaddage W., Sabri A. Revisiting Down syndrome from the ENT perspective: review of literature and recommendations. Eur. Arch. Otorhinolaryngol. 2014, 271:863-869.
78. Rimmer J.H., Yamaki K., Lowry B.M., Wang E., Vogel L.C. Obesity and obesity-related secondary conditions in adolescents with intellectual/developmental disabilities. J. Intellect. Disabil. Res. 2010, 54:787-794.
79. Rodrigues A.N., Coelho L.C., Goncalves W.L., Gouvea S.A., Vasconcellos M.J., Cunha R.S., Abreu G.R. Stiffness of the large arteries in individuals with and without Down syndrome. Vasc. Health Risk Manag. 2011, 7:375-381.
80. Rubin S.S., Rimmer J.H., Chicoine B., Braddock D., McGuire D.E. Overweight prevalence in persons with Down syndrome. Ment. Retard. 1998, 36:175-181.
81. Rumble B., Retallack R., Hilbich C., Simms G., Multhaup G., Martins R., Hockey A., Montgomery P., Beyreuther K., Masters C.L. Amyloid A4 and its precursor in Down's syndrome and Alzheimer's disease. N. Engl. J. Med. 1989, 320:1446-1462.
82. Schrager G.O., Cohen S.J., Vigman M.P. Acute hemiplegia and cortical blindess due to moyamoya disease: report of a case in a child with Down's syndrome. Pediatrics 1977, 60:33-37.
83. Schupf N., Zigman W.B., Tang M.X., Pang D., Mayeux R., Mehta P., Silverman W. Change in plasma Ass peptides and onset of dementia in adults with Down syndrome. Neurology 2010, 75:1639-1644.
84. Schupf N., Lee J.H., Wei M., Pang D., Chace C., Cheng R., Zigman W.B., Tycko B., Silverman W. Estrogen receptor-alpha variants increase risk of Alzheimer's disease in women with Down syndrome. Dement. Geriatr. Cogn. Disord. 2008, 25:476-482.
85. Schupf N., Sergievsky G.H. Genetic and host factors for dementia in Down's syndrome. Br. J. Psychiatry 2002, 180:405-410.
86. Shott S.R., Amin R., Chini B., Heubi C., Hotze S., Akers R. Obstructive sleep apnea: should all children with Down syndrome be tested?. Arch. Otolaryngol. Head Neck Surg. 2006, 132:432-436.
87. Stoll C., Alembik Y., Dott B., Roth M.P. Study of Down syndrome in 238,942 consecutive births. Ann. Genet. 1998, 41:44-51.
88. Stoltzner S.E., Grenfell T.J., Mori C., Wisniewski K.E., Wisniewski T.M., Selkoe D.J., Lemere C.A. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am. J. Pathol. 2000, 156:489-499.
89. Styles M.E., Cole T.J., Dennis J., Preece M.A. New cross sectional stature, weight, and head circumference references for Down's syndrome in the UK and Republic of Ireland. Arch. Dis. Child. 2002, 87:104-108.
90. Sudduth T.L., Greenstein A., Wilcock D.M. Intracranial injection of gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Abeta in APP/PS1 mice along a different time course than anti-Abeta antibodies. J. Neurosci. 2013, 33:9684-9692.
91. Sudduth T.L., Schmitt F.A., Nelson P.T., Wilcock D.M. Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol. Aging 2013, 34:1051-1059.
92. Sudduth T.L., Weekman E.M., Brothers H.M., Braun K., Wilcock D.M. Beta-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice. Alzheimers Res. Ther. 2014, 6:32.
93. Suzuki J., Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch. Neurol. 1969, 20:288-299.
94. Tansley G., Holmes D.T., Lutjohann D., Head E., Wellington C.L. Sterol lipid metabolism in Down syndrome revisited: Down syndrome is associated with a selective reduction in serum brassicasterol levels. Curr. Gerontol. Geriatr. Res. 2012, 2012:179318.
95. Trois M.S., Capone G.T., Lutz J.A., Melendres M.C., Schwartz A.R., Collop N.A., Marcus C.L. Obstructive sleep apnea in adults with Down syndrome. J. Clin. Sleep Med. 2009, 5:317-323.
96. van Erven P.M., Gabreels F.J., Thijssen H.O., Renier W.O. The Moya-moya syndrome: a report of two children. Clin. Neurol. Neurosurg. 1982, 84:179-189.
97. van Gameren-Oosterom H.B., van Dommelen P., Schonbeck Y., Oudesluys-Murphy A.M., van Wouwe J.P., Buitendijk S.E. Prevalence of overweight in Dutch children with Down syndrome. Pediatrics 2012, 130:e1520-e1526.
98. Vianello E., Dogliotti G., Dozio E., Corsi Romanelli M.M. Low heart-type fatty acid binding protein level during aging may protect Down syndrome people against atherosclerosis. Immun. Ageing 2013, 10:2.
99. Vinters H.V. Cerebral amyloid angiopathy. Stroke 1987, 18:311-324.
100. Vis J.C., Duffels M.G., Winter M.M., Weijerman M.E., Cobben J.M., Huisman S.A., Mulder B.J. Down syndrome: a cardiovascular perspective. J. Intellect. Disabil. Res. 2009, 53:419-425.
101. Wilcock D.M. Neuroinflammation in the aging Down syndrome brain; lessons from Alzheimer's disease. Curr. Gerontol. Geriatr. Res. 2012, 2012:170276.
102. Wilcock D.M. Neuroinflammatory phenotypes and their roles in Alzheimer's disease. Neurodegener. Dis. 2014, 13:183-185.
103. Wilcock D.M., Griffin W.S. Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J. Neuroinflammation 2013, 10:84.
104. Wilcock D.M., Zhao Q., Morgan D., Gordon M.N., Everhart A., Wilson J.G., Lee J.E., Colton C.A. Diverse inflammatory responses in transgenic mouse models of AD and the effect of immunotherapy on these responses. ASN Neuro. 2011.
105. Wilcock D.M., Hurban J., Helman A.M., Sudduth T.L., McCarty K.L., Beckett T.L., Ferrell J.C., Murphy M.P., Abner E.L., Schmitt F.A., Head E. Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease. Neurobiol. Aging 2015, 36:2468-2474.
106. Wisniewski K., Wisniewski H., Wen G. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 1985, 17:278-282.
107. Wisniewski K., Howe J., Williams G., Wisniewski H.M. Precocious aging and dementia in patients with Down's syndrome. Biol. Psychiatry 1978, 13:619-627.
108. Yaffe K., Laffan A.M., Harrison S.L., Redline S., Spira A.P., Ensrud K.E., Ancoli-Israel S., Stone K.L. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 2011, 306:613-619.
109. Yla-Herttuala S., Luoma J., Nikkari T., Kivimaki T. Down's syndrome and atherosclerosis. Atherosclerosis 1989, 76:269-272.
110. Yla-Herttuala S., Luoma J., Nikkari T., Kivimaki T. Down's syndrome and atherosclerosis. Atherosclerosis 1989, 76:269-272.
111. Zhao Q., Lee J.H., Pang D., Temkin A., Park N., Janicki S.C., Zigman W.B., Silverman W., Tycko B., Schupf N. Estrogen receptor-beta variants are associated with increased risk of Alzheimer's disease in women with Down syndrome. Dement. Geriatr. Cogn. Disord. 2011, 32:241-249.
112. Zigman W.B. Atypical aging in Down syndrome. Dev. Disabil. Res. Rev. 2013, 18:51-67.